TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
Sports
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | United StatesPakistan
Diaspora
Features | Time CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
UPSC | Exam ScheduleExam Mentor
Advertisement

Manufacturers told to slash price of 3 cancer drugs

The National Pharmaceutical Pricing Authority (NPPA) on Tuesday issued a memorandum directing drug manufacturers to reduce the MRP on three anti-cancer drugs — Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Budget for 25...
Photo for representational purpose only.
Advertisement

The National Pharmaceutical Pricing Authority (NPPA) on Tuesday issued a memorandum directing drug manufacturers to reduce the MRP on three anti-cancer drugs — Trastuzumab, Osimertinib and Durvalumab.

Advertisement

This is in pursuance to the announcement made in the Budget for 25 exempting these three anti-cancer medicines from customs duty. The Finance Ministry had in July issued a notification reducing the customs duty to nil on these three anticancer drugs.

Advertisement

Further, the Department of Revenue, Ministry of Finance, issued notification on October 8 notifying the reduction in GST Rates from 12 per cent to 5 per cent.

Accordingly, there should be a reduction in the MRP of these drugs and the benefits of reduced duties should be passed on to consumers, the government said.

Advertisement
Advertisement
Show comments
Advertisement